NCT06282731

The Changes of Urine Growth Factors Level

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia After Medical Treatment

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: En Chu Kong Hospital · Academic / Other
• Sex: Male
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia after medical treatment.

Detailed description

The prevalence of benign prostate hyperplasia, like medical illness such as hypertension, diabetes mellitus and stroke, increase by age. Benign prostate hyperplasia will cause bothersome lower urinary tract symptoms in the middle and aged male. Previous studies have showed that overactive bladder syndrome (urge, frequency, nocturia or urinary incontinence) has been considered as an important factor to predict successful treatment. Urine nerve growth factor level, brain-derived neurotrophic factor and endothelium vascular growth factor have been proved as a simple and noninvasive biomarker for diagnosing overactive bladder. As a result, investigator will investigate the changes of these growth factors level in patients with benign prostate hyperplasia before and after three and six-months medical treatment. In addition, investigator can understand whether overactive bladder will have effects on successful medical treatment in patients with benign prostate hyperplasia.

Conditions

• Benign Prostatic Hyperplasia

Interventions

Type	Name	Description
DRUG	Silodosin	Indications:Benign prostate hyperplasia

Timeline

• Start date: 2013-05-31
• Primary completion: 2016-09-01
• Completion: 2017-04-27
• First posted: 2024-02-28
• Last updated: 2024-02-28

Locations

1 site across 1 country: Taiwan